Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative - PubMed (original) (raw)

Review

Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative

Cameron S Carter et al. Schizophr Bull. 2007 Sep.

Abstract

The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.

PubMed Disclaimer

Similar articles

• Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
  Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Goldberg TE, et al. Arch Gen Psychiatry. 2007 Oct;64(10):1115-22. doi: 10.1001/archpsyc.64.10.1115. Arch Gen Psychiatry. 2007. PMID: 17909123 Clinical Trial.
• Important steps in the development of cognitive-enhancing drugs in schizophrenia.
  Buchanan RW. Buchanan RW. Am J Psychiatry. 2006 Nov;163(11):1867-9. doi: 10.1176/ajp.2006.163.11.1867. Am J Psychiatry. 2006. PMID: 17074932 No abstract available.
• Executive functioning component mechanisms and schizophrenia.
  Kerns JG, Nuechterlein KH, Braver TS, Barch DM. Kerns JG, et al. Biol Psychiatry. 2008 Jul 1;64(1):26-33. doi: 10.1016/j.biopsych.2008.04.027. Biol Psychiatry. 2008. PMID: 18549874
• Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
  Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Carter CS, et al. Biol Psychiatry. 2008 Jul 1;64(1):4-10. doi: 10.1016/j.biopsych.2008.03.020. Epub 2008 May 7. Biol Psychiatry. 2008. PMID: 18466880 Free PMC article.
• Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.
  Moore H, Geyer MA, Carter CS, Barch DM. Moore H, et al. Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2087-91. doi: 10.1016/j.neubiorev.2013.09.011. Epub 2013 Sep 30. Neurosci Biobehav Rev. 2013. PMID: 24090823 Free PMC article.

Cited by

• Interaction between BDNF Val66Met polymorphism and mismatch negativity for working memory capacity in schizophrenia.
  Hou W, Qin X, Li H, Wang Q, Ding Y, Chen X, Wang R, Dong F, Bo Q, Li X, Zhou F, Wang C. Hou W, et al. Schizophrenia (Heidelb). 2024 Aug 22;10(1):70. doi: 10.1038/s41537-024-00493-x. Schizophrenia (Heidelb). 2024. PMID: 39174571 Free PMC article.
• Neurocognitive, Clinical and Reelin Activity in Rehabilitation Using Neurofeedback Therapy in Patients with Schizophrenia.
  Markiewicz R, Markiewicz-Gospodarek A, Trubalski M, Łoza B. Markiewicz R, et al. J Clin Med. 2024 Jul 10;13(14):4035. doi: 10.3390/jcm13144035. J Clin Med. 2024. PMID: 39064075 Free PMC article.
• National Institute of Mental Health Support for Cognitive Treatment Development in Schizophrenia: A Narrative Review.
  Heinssen RK, Morris SE, Sherrill JT. Heinssen RK, et al. Schizophr Bull. 2024 Aug 27;50(5):972-983. doi: 10.1093/schbul/sbae109. Schizophr Bull. 2024. PMID: 38941445 Review.
• Personalized Cognitive Health in Psychiatry: Current State and the Promise of Computational Methods.
  Chen CS, Vinogradov S. Chen CS, et al. Schizophr Bull. 2024 Aug 27;50(5):1028-1038. doi: 10.1093/schbul/sbae108. Schizophr Bull. 2024. PMID: 38934792 Review.
• Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
  Siafis S, McCutcheon R, Chiocchia V, Ostinelli EG, Wright S, Stansfield C, Juma DO, Mantas I, Howes OD, Rutigliano G, Ramage F, Tinsdeall F, Friedrich C, Milligan L, Moreno C, Elliott JH, Thomas J, Macleod MR, Sena ES, Seedat S, Salanti G, Potts J, Cipriani A, Leucht S; GALENOS team. Siafis S, et al. Wellcome Open Res. 2023 Aug 25;8:365. doi: 10.12688/wellcomeopenres.19866.1. eCollection 2023. Wellcome Open Res. 2023. PMID: 38634067 Free PMC article.

References

1. 1. Green MF. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51. - PubMed
2. 1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330. - PubMed
3. 1. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry. 2006;67:e11. - PubMed
4. 1. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004;174:25–31. - PubMed
5. 1. Roth BL. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004;174:17–24. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information